Regeneron says its COVID-19 antibody treatment cut medical visits in trial
Corrects trial size
Oct 28 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O said on Wednesday that its COVID-19 antibody cocktail - the experimental treatment that U.S. President Donald Trump received - significantly reduced medical visits in a trial of around 800 patients with mild-to-moderate sickness.
The company said it has shared the results with the U.S. Food and Drug Administration as part of its review of the company's request for emergency use authorization of the treatment.
(Reporting by Michael Erman; Editing by Leslie Adler)
((michael.erman@thomsonreuters.com; +1 646-223-6021; Reuters Messaging: michael.erman.thomsonreuters.com@thomsonreuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In This Story
REGNLatest Markets Videos
Explore US Markets
ExploreMost Popular
- Tesla removed from S&P 500 ESG index on autopilot, discrimination concerns
- Fed could cut rates in 2023, 2024 once inflation under control -Bullard
- US STOCKS-Wall Street ends sharply lower as Target and growth stocks sink
- Powell says Fed to 'keep pushing' rates higher until clear inflation is falling